<DOC>
	<DOCNO>NCT01454791</DOCNO>
	<brief_summary>The purpose study assess effect Diclofenac Sodium Topical Gel ( DSTG ) injection site reaction follow self-administer glatiramer acetate people Multiple Sclerosis .</brief_summary>
	<brief_title>Diclofenac Sodium Topical Gel Reduce Injection Site Discomfort Patients Taking Glatiramer Acetate</brief_title>
	<detailed_description>A 4 week study active placebo medication randomization switch treatment 2-week crossover visit ( 2 week arm ) . There total 3 visit clinic . Subjects receive instruction apply DSTG/placebo injection site keep daily injection site reaction diary .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Diclofenac</mesh_term>
	<mesh_term>Glatiramer Acetate</mesh_term>
	<criteria>Diagnosis Multiple Sclerosis ( MS ) make least 3 month prior base McDonald Poser criterion . Age 18 Ongoing treatment glatiramer acetate ( Copaxone ) three month . No MS exacerbation 60 day prior screen . Mean score great equal 1.0 screen Local Injection Site Reaction scale last 3 day . Written informed consent . Regular use nonsteroidal antiinflammatory drug ( NDAID ) , except Asprin ( &lt; 325 mg daily ) , screen end study . Any contraindication Diclofenac Sodium Topical Gel ( DSTG ) allergy DSTG NSAID . history asthma , urticaria , allergic reaction take NSAID . Females breast feeding , pregnant potential become pregnant course study ( fertile unwilling/unable use effective contraceptive measure ) . Cognitive deficit would interfere subject 's ability give inform consent preform study test . Any serious and/or unstable medical condition .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>multiple sclerosis</keyword>
	<keyword>diclofenac</keyword>
	<keyword>subcutaneous injection</keyword>
	<keyword>glatiramer acetate</keyword>
	<keyword>Copaxone</keyword>
</DOC>